Penumbra (NYSE:PEN) posted second-quarter results this week that beat the overall consensus on Wall Street.
The Alameda, Calif.-based vascular conditions device company reported profits of $9.2 million, or 25¢ per share, on sales of $184.3 million for the three months ended June 30, for a sales growth of 75.3% compared with Q2 2020.
Adjusted to exclude one-time items, earnings per share were 21¢, 4¢ ahead of The Street, where analysts were looking for sales of $170.76 million.
Penumbra is increasing its full-year 2021 revenue guidance to be in the range of $720 million to $730 million.
Shares in PEN were up 4.73% to $276.12 apiece at market open.
